Simar Pal Singh

Simar Pal Singh

Auto-generated profile, based on publicly available information

Simar Pal Singh

PamGene International BV, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JRJasper Rip
Jasper Rip
MBMarjolein J. W. de Bruijn
Marjolein J. W. de Bruijn
SNStefan F.H. Neys
Stefan F.H. Neys
SSSimar Pal Singh
Simar Pal Singh
JWJonas Willar
Jonas Willar
Odilia CornethOdilia Corneth
Odilia Corneth
Bruton′s tyrosine kinase (Btk) is a crucial signaling molecule in BCR signaling and a key regulator of B‐ cell differentiation and function. Btk inhibition has shown impressive clinical efficacy in various B‐cell malignancies. However, it remains unknown whether inhibition additionally induces changes in BCR signaling due to feedback mechanisms, a phenomenon referred to as BCR rewiring. In this report, we studied the impact of Btk activity on major components of the BCR signaling pathway in mice. As expected, NF‐κB and Akt/S6 signaling was decreased in Btk‐deficient B cells. Unexpectedly, phosphorylation of several proximal signaling molecules, including CD79a, Syk, and PI3K, as well as the key Btk‐effector PLCγ2 and the more downstream kinase Erk, were significantly increased. This pattern of BCR rewiring was essentially opposite in B cells from transgenic mice overexpressing Btk. Importantly, prolonged Btk inhibitor treatment of WT mice or mice engrafted with leukemic B cells also resulted in increased phosho‐CD79a and phospho‐PLCγ2 in B cells. Our findings show that Btk enzymatic function determines phosphorylation of proximal and distal BCR signaling molecules in B cells. We conclude that Btk inhibitor treatment results in rewiring of BCR signaling, which may affect both malignant and healthy B cells.

15 January 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SSSimar Pal Singh
Simar Pal Singh
MBMarjolein J. W. de Bruijn
Marjolein J. W. de Bruijn
CGCatarina Velaso Gago da Graça
Catarina Velaso Gago da Graça
OCOdilia B. J. Corneth
Odilia B. J. Corneth
JRJasper Rip
Jasper Rip
Rudi HendriksRudi Hendriks
Rudi Hendriks
Balanced activity of kinases and phosphatases downstream of the BCR is essential for B cell differentiation and function and is disturbed in chronic lymphocytic leukemia (CLL). In this study, we employed IgH.TEμ mice, which spontaneously develop CLL, and stable EMC CLL cell lines derived from these mice to explore the role of phosphatases in CLL. Genome-wide expression profiling comparing IgH.TEμ CLL cells with wild-type splenic B cells identified 96 differentially expressed phosphatase genes, including SH2-containing inositol phosphatase (Ship2). We found that B cell–specific deletion of Ship2, but not of its close homolog Ship1, significantly reduced CLL formation in IgH.TEμ mice. Treatment of EMC cell lines with Ship1/2 small molecule inhibitors resulted in the induction of caspase-dependent apoptosis. Using flow cytometry and Western blot analysis, we observed that blocking Ship1/2 abrogated EMC cell survival by exerting dual effects on the BCR signaling cascade. On one hand, specific Ship1 inhibition enhanced calcium signaling and thereby abrogated an anergic response to BCR stimulation in CLL cells. On the other hand, concomitant Ship1/Ship2 inhibition or specific Ship2 inhibition reduced constitutive activation of the mTORC1/ribosomal protein S6 pathway and downregulated constitutive expression of the antiapoptotic protein Mcl-1, in both EMC cell lines and primary IgH.TEμ CLL cells. Importantly, also in human CLL, we found overexpression of many phosphatases including SHIP2. Inhibition of SHIP1/SHIP2 reduced cellular survival and S6 phosphorylation and enhanced basal calcium levels in human CLL cells. Taken together, we provide evidence that SHIP2 contributes to CLL pathogenesis in mouse and human CLL. Key Points B cell–specific deletion of Ship2 phosphatase reduces CLL formation in a mouse model. Ship2 inhibition reduces Akt/mTORC1/S6 signaling in murine and human CLL cells. Ship2 supports survival of CLL cells via the key antiapoptotic protein Mcl-1.

23 April 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
EVEetu Valkama
Eetu Valkama
ETElisa Toropainen
Elisa Toropainen
SSSimar Pal Singh
Simar Pal Singh
AVAnnika Valtari
Annika Valtari
AKAli Koskela
Ali Koskela
JPJooseppi Puranen
Jooseppi Puranen
Retinitis pigmentosa (RP) is an inherited and untreatable retinal dystrophy that leads to blindness at an early age. Cyclic guanosine monophosphate analogue, 8- bromo- β- phenyl- 1, N²- ethenoguanosine- 3', 5'- cyclic monophosphorothioate Rp- isomer (CN03), has shown preclinical promise as systemic treatment in an RP mouse model. We explored intravitreal (IVT) CN03 delivery and resulting biochemical responses in rabbits. To prolong activity, we used poorly water-soluble benethamine (BNE) and benzathine (BNZ) salts to sustain CN03 release. Crystallinity, particle size, and solubility of CN03-BNE (385.4 ± 37.07 µM) and CN03-BNZ (275.9 ± 9.24 µM) in vitreous humor were determined. Suspension of 15% CN03-BNZ showed dissolution half-life of 7.40 ± 0.86 days in vitro and CN03 release of one month after IVT injection in rabbits. Ex vivo in retina lysates, CN03 showed concentration-dependent inhibition of PKG kinases. Furthermore, downregulation of PKG-related kinases and RP-linked cellular pathways (e.g., calmodulin, PI3K-AKT-mTOR, and NF-κB) in rabbit retina and peripheral blood monocytes (PBMC) were seen after IVT injection of CN03-BNZ suspension. Kinase inhibition profiles in the retina and PBMCs overlapped, but plasma CN03 levels were much lower than in the retina. PBMC kinase activity is a potential biomarker for retinal kinase inhibition, warranting further studies in disease state models. Overall, intravitreal delivery of cGMP analogue CN03 as a poorly water-soluble salt demonstrates kinase inhibition and sustained ocular delivery. These results lay the foundation for further translational studies towards intravitreal treatment of the RP with cGMP analogues.